Bioventix Regulatory News (BVXP)

Bioventix plc ("Bioventix" or the "Company") Director dealing Bioventix plc (AIM: BVXP) was notified on 16 April 2015 that on the same day,due to institutional investor demand, the following director dealt in theordinary shares of 5 pence each ("Ordinary Shares") in the Company: Name Position Type of Number of Price Ordinary Percentage transaction Ordinary per shares and of Ordinary Shares Ordinary voting Shares and Share rights held voting (pence) following rights held the following transaction the transaction Peter Chief Disposal 100,000* 800 661,176 13.1%Harrison Executive * 3,000 of which were held in the name of his wife For further information please contact: Bioventix plc Chief Executive Officer Tel: 01252 728 001Peter Harrison finnCap Ltd Corporate Finance Tel: 020 7220 0500Geoff Nash/Simon Hicks Corporate BrokingSteve Norcross About Bioventix plc: Bioventix (www.bioventix.com) specialises in the development and commercialsupply of high-affinity monoclonal antibodies with a primary focus on theirapplication in clinical diagnostics, such as in automated immunoassays used inblood testing. The antibodies created at Bioventix are generated in sheep andare of particular benefit where the target is present at low concentration andwhere conventional monoclonal or polyclonal antibodies have failed to produce asuitable reagent. Bioventix currently offers a portfolio of antibodies tocustomers for both commercial use and R&D purposes, for the diagnosis ormonitoring of a broad range of conditions, including heart disease, cancer,fertility, thyroid function and drug abuse. Bioventix currently suppliesantibody products and services to the majority of multinational clinicaldiagnostics companies. Bioventix is based in Farnham, UK and its shares aretraded on AIM under the symbol BVXP.